UCBJY News and Press, UCB S.A. ADR From 06/27/23

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis PR Newswire FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treat...

2023-06-05 05:02:09 ET Summary ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The company has entered into pre-clinical work and milest...

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting PR Newswire New insights from leading portfolio demonstrate ongoing commitment to improving outcomes and experiences of those living with epilepsy and rare epilep...

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance PR Newswire ATLANTA , April 17, 2023 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U...

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks PR Newswire Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningf...

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa PR Newswire Phase 3 data on investigational bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa ...

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...

Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis PR Newswire Publication of 24-week results from the BE MOBILE 1 and BE MOBILE 2 studies, evaluating bimekizumab, an IL-17A and IL-17F inhibitor, across the full s...

Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...